Proton therapy technology developer Ion Beam Applications has wrapped up the divestiture of its IBA Molecular joint venture.
IBA sold its 40% stake in IBA Molecular to investment funds advised by CapVest Partners for 62 million euros in cash. As a result, IBA has fully exited its joint venture with SK Capital Partners and retains no interest in the company.
The move enables IBA to focus its business on proton therapy, according to the vendor.
